Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bio Essence (BIOE) Common Equity (2020 - 2025)

Bio Essence (BIOE) has 6 years of Common Equity data on record, last reported at -$3.1 million in Q3 2025.

  • For Q3 2025, Common Equity fell 5.45% year-over-year to -$3.1 million; the TTM value through Sep 2025 reached -$3.1 million, down 5.45%, while the annual FY2024 figure was -$3.0 million, 78.83% down from the prior year.
  • Common Equity reached -$3.1 million in Q3 2025 per BIOE's latest filing, roughly flat from -$3.1 million in the prior quarter.
  • Across five years, Common Equity topped out at -$1.2 million in Q2 2023 and bottomed at -$3.4 million in Q1 2023.
  • Average Common Equity over 5 years is -$2.5 million, with a median of -$2.7 million recorded in 2022.
  • Peak YoY movement for Common Equity: skyrocketed 59.24% in 2023, then crashed 108.0% in 2025.
  • A 5-year view of Common Equity shows it stood at -$2.4 million in 2021, then crashed by 33.34% to -$3.2 million in 2022, then soared by 48.73% to -$1.7 million in 2023, then crashed by 78.83% to -$3.0 million in 2024, then decreased by 4.48% to -$3.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$3.1 million in Q3 2025, -$3.1 million in Q2 2025, and -$3.2 million in Q1 2025.